Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

Revuelta-Herrero, José Luis; Giménez‐Manzorro, Álvaro; Matilla-Peña, A.M.; Herranz‐Alonso, Ana; Sanjurjo‐Sáez, María

doi:10.1111/jcpt.12727

Cited by 5 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one of them, although only three patients were included, the SVR rate was 100%, and the combination was considered safe and effective. However, at the time of DAA initiation, the patients did not have active or residual HCC lesions 56 . Another study that included 368 patients of whom 14.3% received sorafenib, showed an SVR rate of 59% 30 …”

Section: Treatment Of Hepatitis C Virus In Advanced Hepatocellular Carcinomamentioning

confidence: 99%

Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?

Mocan

Nenu

Crăciun

et al. 2021

J of Gastro and Hepatol

View full text Add to dashboard Cite

The discovery of direct acting antivirals (DAA) with high rates of sustained virusological response is the biggest epoch‐making event in the history of hepatitis C virus (HCV) treatment. DAAs improve liver function, prevent hepatic decompensation, and might even reverse liver fibrosis. Although initial research pointed towards a potential drawback, it is now known beyond doubt that DAA treatment reduces hepatocellular carcinoma (HCC) occurrence or recurrence after curative treatments. Unfortunately, the story has reached another plot twist, as several other issues have emerged: (i) Should we treat patients with early HCC and HCV before or after surgery/ablation? (ii) Should patients with HCC on the waiting list receive DAA before or after liver transplantation? (iii) Should we use interferon‐free in patients with intermediate stage HCC or in patients under systemic treatments? In this review, we aim to offer some evidence‐based answers to these changing clinical dilemmas where possible, or at least some educated guesses in cases were no or little data exists.

show abstract

Section: Treatment Of Hepatitis C Virus In Advanced Hepatocellular Carcinomamentioning

confidence: 99%

Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?

Mocan

Nenu

Crăciun

et al. 2021

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…As many trials for the new DAA regimens excluded patients with HCC, there is a little data on the interaction between targeted therapies and DAAs [68] . One small case series noted that there were no deleterious effects in combining ombitasvir/paritaprevir/ritonavir and dasabuvir, either in terms of antineoplastic effect or SVR rate [69] , but more studies are required to assess these interactions.…”

Section: Daas and Systemic Therapiesmentioning

confidence: 99%

Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review

Harrod¹,

Moctezuma‐Velázquez²,

Gürakar³

et al. 2019

View full text Add to dashboard Cite

Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa, highlighting the ongoing complexity of this clinical scenario. There remain multiple unanswered questions when considering the management of these complex patients and, with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma, these questions are only going to grow. Treatment timing, interactions and the impact of one disease condition on the other are vitally important, though guidance generally remains non-specific, suggesting that we make these decisions on a case-by-case basis. We focus on the current evidence for managing these cases, depending on disease stage and treatment type. BACKGROUND Hepatitis C virus (HCV) accounts for a third of all hepatocellular carcinoma (HCC) cases worldwide, with a 1%-8% annual risk of HCC development in cirrhotic HCV-infected patients [1-4] . The presence of cirrhosis greatly increases the risk of HCC development in HCV-positive patients, with the prominent pro-DECLARATIONS

show abstract

Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East

Al-Busafi

Al-Naamani²

2021

Liver Cancer in the Middle East

View full text Add to dashboard Cite

Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

Abstract: The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective.

Cited by 5 publications

References 13 publications

Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?

Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?

Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review

Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East

Contact Info

Product

Resources

About